Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study.
二型糖尿病老年患者中達帕格列酮與DPP-4抑制劑的短期療效：多中心回顧性研究。
J Endocrinol Invest 2023-06-16
Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System.
使用FDA不良事件報告系統比較糖尿病患者在使用二肽基胜肽酶-4抑制劑期間發生的不良事件。
Clin Drug Investig 2023-02-08
Do DPP-4 enzyme inhibitors affect hemoglobin, leucocyte and thrombocyte levels in patients with type 2 diabetes mellitus?
DPP-4 酶抑制劑是否會影響2型糖尿病患者的血紅素、白細胞和血小板水平？
Eur Rev Med Pharmacol Sci 2023-08-20
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature.
DPP-4 抑制劑治療 T2DM - 炒作還是希望？基於目前文獻的分析。
Front Mol Biosci 2023-06-10
Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis.
二型糖尿病中二肽基胺基肽酶-4抑制劑對葡萄糖依賴性胰島素增生多肽的影響：系統性回顧與荟萃分析。
Front Endocrinol (Lausanne) 2023-09-12
Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.
糖尿病患者使用二肽基胜肽酶-4抑制劑與帕金森病風險降低相關。
Sci Rep 2023-12-28
Pancreatitis and Pancreatic Cancer Risk Among Patients With Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors: An Updated Meta-Analysis of Randomized Controlled Trials.
接受二肽基肽酶 4 抑制劑的 2 型糖尿病患者中胰臟炎與胰臟癌風險：隨機對照試驗的更新型統合分析。
Clin Ther 2024-07-31
New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control.
超越血糖控制的二肽基肽酶-4抑制劑多重作用的新見解。
touchREV Endocrinol 2024-11-11